Videos

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.

Declan Murphy talked about the future of PSMA theranostics to target metastatic castration-resistant prostate cancer.

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed exciting treatment options for patients with multiple myeloma that are being presented at ASH this year.

Narayan discusses what he thinks the future of nadofaragene firadenovec and bladder cancer are at this year’s SUO Meeting.

The expert from Cedars-Sinai Cancer spoke about the continued integration of immunotherapy-based combination regimens, and the importance of utilizing the multidisciplinary care team to mitigate any possible toxicities that may arise.

The clinical researcher spoke about the research that she is most excited to review at ASH this year.

Research from a pilot trial presented at the 2020 American Society of Hematology (ASH) Annual Meeting found above average complete response and disease-free survival rates for patients with DLBCL.

The study assessed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center.

The preliminary findings of the extension arm of the phase 2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin (Polivy) plus bendamustine (Bendeka) and rituximab (Rituxan) for patients with diffuse large B cell lymphoma.

An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and high-risk genomic features.

This pooled analysis from 4 clinical trials suggested that though patients with TP53 aberrations remain at risk for progression, first-line treatment with ibrutinib has meaningfully improved the poor prognosis in this high-risk population.

The myeloma expert discussed the randomized, open label study measuring the safety and efficacy of daratumumab (Darzalex) plus RVd for patients with newly diagnosed multiple myeloma.

The study sought to determine the impact of a rurally focused telemedicine program on patient outcomes.

The lymphoma expert spoke about the research being presented at the 2020 ASH Annual Meeting and what he believes has the potential to be most influential for treating this patient population.

The leukemia expert discussed exciting research being presented at this year’s ASH Annual Meeting.

The kidney cancer expert from the National Cancer Institute spoke about what ongoing research in the field of kidney cancer is most encouraging and where research should continue to be focused.

The assistant professor of Medicine in the division of Hematology and Medical Oncology at Weill Cornell Medicine spoke about exciting research coming out of ASH for patients with chronic lymphocytic leukemia.

Voorhees noted that despite challenges associated with the COVID-19 pandemic, emerging therapies offer hope for patients with multiple myeloma.

Gadzinski spoke about the most exciting aspect of the research coming out of the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

The director of the new Women’s Lung Cancer Program at Mount Sinai spoke about the gaps in lung cancer research for women and what she hopes this new program will offer women moving forward.

Given that smoking is one of the major risk factors for recurrence of any cancer, Tsao explained that it's crucial that providers focus on smoking cessation in patients with cancer.

Given that diagnosing lung cancer in its early stages can lead to successfully eliminating lung cancer with surgery alone, the importance of closing this disparity gap is critical.

The SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team have developed laboratory models to understand the inflammatory process in the lung’s bronchial cells, and how that relates to early lung cancer development.

Ahlstrom explained the necessity of offering patients with cancer telehealth opportunities and what patients with cancer will lose should telehealth waivers expire.

Adil Daud, MD, spoke about the emergence of next-generation sequencing and the importance of testing patients with melanoma for BRAF mutations.

Jeffrey Weber, MD, PhD, discusses the unmet needs professionals take into consideration when deciding treatment options for patients with melanoma.

Research published by Galvin, et al. in the journal ONCOLOGY® demonstrated the necessity to understand why eligible patients with pancreatic adenocarcinoma elect not to participate in early-phase clinical trials.

Data from the COMBI-AD Trial evaluating dabrafenib and trametinib to treat melanoma was analyzed by Hussein Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center.

CancerNetwork spoke with Jason Luke, MD, FACP, at the SMR Conference regarding the latest updates on melanoma.